Lena C. Schröder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lena C. Schröder has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Derk Frank
Department of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein , Campus Kiel, Kiel
1 shared publication - Oliver Josef Müller
Department of Internal Medicine III University of Kiel Kiel Germany
1 shared publication
Latest Publications
- Open Access
Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors
Cardiac-targeted transgene delivery offers new treatment opportunities for cardiovascular diseases, which massively contribute to global mortality. Restricted gene transfer to cardiac tissue might protect extracardiac organs from potential side-effects. This could be mediated by using cis-regulatory elements, including promoters and enhancers that act on the transcriptional level. Here, we discuss examples of tissue-specific promoters for targeted transcription in myocytes, cardiomyocytes, and chamber-specific cardiomyocytes. Some promotors are induced at pathological states, suggesting a potential use as “induction-by-disease switches” in gene therapy. Recent developments have resulted in the identification of novel enhancer-elements that could further pave the way for future refinement of transcriptional targeting, for example, into the cardiac conduction system.
Open AccessTranscriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors
Cardiac-targeted transgene delivery offers new treatment opportunities for cardiovascular diseases, which massively contribute to global mortality. Restricted gene transfer to cardiac tissue might protect extracardiac organs from potential side-effects. This could be mediated by using cis-regulatory elements, including promoters and enhancers that act on the transcriptional level. Here, we discuss examples of tissue-specific promoters for targeted transcription in myocytes, cardiomyocytes, and chamber-specific cardiomyocytes. Some promotors are induced at pathological states, suggesting a potential use as “induction-by-disease switches” in gene therapy. Recent developments have resulted in the identification of novel enhancer-elements that could further pave the way for future refinement of transcriptional targeting, for example, into the cardiac conduction system.